Maxime Ranger

RM-581, a small molecule in early developpement of a new class (the aminosteroids), demonstrated its ability to block the progression or even reduce the size of cancerous tumours that are difficult to treat with conventional chemothérapy. Le RM-581, une petite molécule en développement préclinique dune nouvelle classe (les aminostéroïdes), a démontré une capacité à bloquer la progression ou même réduire réduire la taille des tumeurs cancéreuses difficiles à traiter avec la chimiothérapie classique.

Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

Mperia Therapeutics is the CD36 Therapeutics Development Company. Lead candidates applied to macrophage-driven inflammation via CD36 receptor immuno-metabolism mediation. Showing clear efficacy in pre-clinical models for dry age-related macular degeneration (dry AMD), atherosclerosis and NASH.

Corbin Therapeutics is a spin-off company from AmorChem Fund 1, developing a sophisticated in-vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, from the laboratory of Dr Philippe Gros, Faculty of Medicine, McGill University, leading to a novel anti-inflammatory target in the deubiquitinylation (DUB) family of enzymes, more particularly USP15.

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

Corbin Therapeutics is a spin-off company from AmorChem Fund 1, developing a sophisticated in-vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, from the laboratory of Dr Philippe Gros, Faculty of Medicine, McGill University, leading to a novel anti-inflammatory target in the deubiquitinylation (DUB) family of enzymes, more particularly USP15.

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.

Mperia Therapeutics is the CD36 Therapeutics Development Company. Lead candidates applied to macrophage-driven inflammation via CD36 receptor immuno-metabolism mediation. Showing clear efficacy in pre-clinical models for dry age-related macular degeneration (dry AMD), atherosclerosis and NASH.

RM-581, a small molecule in early developpement of a new class (the aminosteroids), demonstrated its ability to block the progression or even reduce the size of cancerous tumours that are difficult to treat with conventional chemothérapy. Le RM-581, une petite molécule en développement préclinique dune nouvelle classe (les aminostéroïdes), a démontré une capacité à bloquer la progression ou même réduire réduire la taille des tumeurs cancéreuses difficiles à traiter avec la chimiothérapie classique.

Le CQIB est un incubateur d'entreprises spécialisé en sciences de la vie et technologies de la santé. Organisation privée, sans but lucratif, le CQIB bénéficie de l’appui de nombreux partenaires publics et privés. L’incubation d’entreprises est un processus d’accompagnement intensif d’entrepreneurs dans les premières années de la création et du démarrage d’une entreprise. Accompagner, Innover, Développer, tel est notre métier. Accompagner les entreprises en démarrage, qui portent vers les marchés des technologies innovantes, contribuant ainsi au développement de la nouvelle économie. ------------------ CQIB is a business incubator specializing in life sciences and health technology start-ups. A private, not-for-profit organization, CQIB receives support from many public and private partners. Business incubation is an intensive mentoring process for entrepreneurs in the first few years of creating and starting a business. Our mission is to support, innovate, develop, in other words, support start-ups with innovative technologies that will further the development of the new economy.

Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising life science investment opportunities. Genesys is one of the largest Canadian-based venture capital firms exclusively focused on the life sciences industry.